Unicycive regains compliance with Nasdaq minimum market value and bid price rules

Unicycive Therapeutics, Inc.

On Feb 21, 2024, Nasdaq notified Unicycive that it regained compliance with the $35M minimum market value and $1.00 minimum bid price requirements.
Non-compliance notices were originally received on Sept 19, 2023, for both Nasdaq Listing Rules 5550(b)(2) and 5550(a)(2).
The compliance matters are now closed with no further action required.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.